

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



# 國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.\*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

## ANNOUNCEMENT POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, 13 SEPTEMBER 2024

References are made to (i) the notice of the EGM of Sinopharm Group Co. Ltd. (the “**Company**”) dated 29 August 2024; and (ii) the circular of the Company dated 29 August 2024 (the “**Circular**”). Terms used in this announcement shall have the same meanings as defined in the Circular unless the context otherwise requires.

### POLL RESULTS OF THE EGM

The Board is pleased to announce that the EGM was held at 9:30 a.m. on Friday, 13 September 2024 at Meeting Room 1401, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District, Shanghai, the PRC. All resolutions proposed at the EGM were duly passed by way of poll. The Directors, Mr. Chen Qiyu, Mr. Wang Kan, Mr. Wang Peng, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao, have attended the EGM.

The poll results in respect of the resolutions proposed at the EGM are as follows:

ORDINARY RESOLUTIONS		Number of Valid Votes (%)	
		For	Against
1.	To consider and approve (if thought fit) the appointment of Mr. Zhao Bingxiang as a non-executive Director of the sixth session of the Board, and to authorise the Board to determine his remuneration and to authorise any Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.	2,432,282,417 (92.7588%)	189,876,992 (7.2412%)
	As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.		

\* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.

2.	To consider and approve (if thought fit) the appointment of Mr. Lian Wanyong as an executive Director of the sixth session of the Board, and to authorise the Board to determine his remuneration and to authorise any Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.	2,574,961,443 (98.1682%)	48,047,966 (1.8318%)
	As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.		
3.	To consider and approve the appointment of Pan-China Certified Public Accountants LLP as the domestic auditor of the Company for 2024 to hold office until the conclusion of the next annual general meeting of the Company, and the appointment of Confucius International CPA Limited as the international auditor of the Company for 2024 to hold office until the conclusion of the next annual general meeting of the Company, and to ratify and confirm their remunerations determined by the audit committee of the Board.	2,622,623,809 (99.9880%)	313,600 (0.0120%)
	As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.		

As at the date of the EGM, the total number of issued Shares of the Company and the total number of Shares entitling the holders to attend and vote for or against the resolutions proposed at the EGM was 3,120,656,191 Shares. There were no Shares entitling the Shareholders of the Company to attend and abstain from voting in favour of any resolution proposed at the EGM as set out in Rule 13.40 of the Hong Kong Listing Rules, and no holders of Shares that are required under the Hong Kong Listing Rules to abstain from voting. There were no parties who had stated their intention in the Circular to vote against the resolutions proposed at the EGM or to abstain from voting.

Shareholders and authorised proxies holding an aggregate of 2,623,009,409 Shares, representing approximately 84.05 % of the total number of issued Shares of the Company, were present at the EGM. The holding of the EGM was in compliance with the requirements of the Company Law of the PRC and the Articles of Association. The EGM was chaired by Mr. Chen Qiyu, the Vice Chairman of the Board.

In compliance with the requirements of the Hong Kong Listing Rules, Computershare Hong Kong Investor Services Limited, the H share registrar of the Company, acted as scrutineer for the vote-taking at the EGM.

By order of the Board  
**Sinopharm Group Co. Ltd.**  
**Zhao Bingxiang**  
*Chairman*

Shanghai, the PRC  
13 September 2024

*As at the date of this announcement, the executive Director is Mr. Lian Wanyong; the non-executive Directors are Mr. Zhao Bingxiang, Mr. Chen Qiyu, Mr. Wang Kan, Mr. Wang Peng, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive Directors are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.*